Cantor Fitzgerald Assumes Xenon Pharmaceuticals at Overweight
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has assumed Xenon Pharmaceuticals (NASDAQ:XENE) with an Overweight rating.
October 24, 2023 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenon Pharmaceuticals has been given an Overweight rating by Cantor Fitzgerald analyst Josh Schimmer.
Analyst ratings often have a significant impact on a company's stock price. An Overweight rating suggests that the analyst believes the company's stock price will outperform the market in the near future. This could lead to increased investor interest in XENE and potentially a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100